[go: up one dir, main page]

WO2000061129A3 - S-hydroxynefazodone - Google Patents

S-hydroxynefazodone Download PDF

Info

Publication number
WO2000061129A3
WO2000061129A3 PCT/US2000/009374 US0009374W WO0061129A3 WO 2000061129 A3 WO2000061129 A3 WO 2000061129A3 US 0009374 W US0009374 W US 0009374W WO 0061129 A3 WO0061129 A3 WO 0061129A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxynefazodone
nefazodone
treatment
disorders
isomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/009374
Other languages
French (fr)
Other versions
WO2000061129A2 (en
Inventor
Timothy J Barberich
Paul D Rubin
William E Yelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Priority to AU42154/00A priority Critical patent/AU4215400A/en
Priority to JP2000610462A priority patent/JP2002541192A/en
Priority to EP00921897A priority patent/EP1189616A2/en
Priority to CA002369225A priority patent/CA2369225A1/en
Publication of WO2000061129A2 publication Critical patent/WO2000061129A2/en
Anticipated expiration legal-status Critical
Publication of WO2000061129A3 publication Critical patent/WO2000061129A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The S-isomer of the hydroxy metabolite of nefazodone, S-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. S-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.
PCT/US2000/009374 1999-04-09 2000-04-07 S-hydroxynefazodone Ceased WO2000061129A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU42154/00A AU4215400A (en) 1999-04-09 2000-04-07 S-hydroxynefazodone
JP2000610462A JP2002541192A (en) 1999-04-09 2000-04-07 S-hydroxynefazodone
EP00921897A EP1189616A2 (en) 1999-04-09 2000-04-07 S-hydroxynefazodone
CA002369225A CA2369225A1 (en) 1999-04-09 2000-04-07 S-hydroxynefazodone

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12848199P 1999-04-09 1999-04-09
US60/128,481 1999-04-09

Publications (2)

Publication Number Publication Date
WO2000061129A2 WO2000061129A2 (en) 2000-10-19
WO2000061129A3 true WO2000061129A3 (en) 2002-01-17

Family

ID=22435569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/009374 Ceased WO2000061129A2 (en) 1999-04-09 2000-04-07 S-hydroxynefazodone

Country Status (6)

Country Link
US (1) US6465469B1 (en)
EP (1) EP1189616A2 (en)
JP (1) JP2002541192A (en)
AU (1) AU4215400A (en)
CA (1) CA2369225A1 (en)
WO (1) WO2000061129A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE50312523D1 (en) * 2002-05-24 2010-04-29 Carl-Fr Coester Pharmaceutical Composition and its use
WO2012072665A1 (en) 2010-11-30 2012-06-07 Pharmaneuroboost N.V. Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338317A (en) * 1981-03-16 1982-07-06 Mead Johnson & Company Phenoxyethyl-1,2,4,-triazol-3-one antidepressants
US4613600A (en) * 1983-09-30 1986-09-23 Mead Johnson & Company Antidepressant 1,2,4-triazolone compounds
US5256664A (en) * 1992-04-28 1993-10-26 Bristol-Myers Squibb Company Antidepressant 3-halophenylpiperazinylpropyl derivatives of substituted triazolones and triazoldiones
US5788986A (en) * 1995-04-06 1998-08-04 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression using R enantiomers, S enantiomers, and racemic mixtures of selective serotonin reuptake inhibitor compounds or their active metabolites

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116852A (en) 1990-12-03 1992-05-26 Bristol-Myers Squibb Co. Treatment of sleep disorders
IT1256387B (en) 1992-11-13 1995-12-04 Acraf PROCEDURE FOR PREPARING TRIAZOLONI
US5691324A (en) 1994-01-14 1997-11-25 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
CA2187989A1 (en) 1995-10-17 1997-04-18 Ronald N. Marcus Nefazodone: treatment of panic attack
US5854248A (en) 1996-07-31 1998-12-29 Bristol-Myers Squibb Company Nefazodone: use in migraine prophylaxis
US5852020A (en) 1996-11-22 1998-12-22 Bristol-Myers Squibb Company Nefazodone: use in treating post traumatic stress disorder

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338317A (en) * 1981-03-16 1982-07-06 Mead Johnson & Company Phenoxyethyl-1,2,4,-triazol-3-one antidepressants
US4613600A (en) * 1983-09-30 1986-09-23 Mead Johnson & Company Antidepressant 1,2,4-triazolone compounds
US5256664A (en) * 1992-04-28 1993-10-26 Bristol-Myers Squibb Company Antidepressant 3-halophenylpiperazinylpropyl derivatives of substituted triazolones and triazoldiones
US5788986A (en) * 1995-04-06 1998-08-04 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression using R enantiomers, S enantiomers, and racemic mixtures of selective serotonin reuptake inhibitor compounds or their active metabolites

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CYR M ET AL: "NEFAZODONE: ITS PLACE AMONG ANTIDEPRESSANTS", ANNALS OF PHARMACOTHERAPY,XX,XX, vol. 30, no. 9, 1 September 1996 (1996-09-01), pages 1006 - 1012, XP000613004, ISSN: 1060-0280 *
GREENE D S ET AL: "Clinical pharmacokinetics of nefazodone.", CLINICAL PHARMACOKINETICS, (1997 OCT) 33 (4) 260-75. REF: 51, XP000911986 *
MALIK, KEMAL: "Nefazodone: structure, mode of action and pharmacokinetics", J. PSYCHOPHARMACOL., vol. 10 (Suppl. 1), 1996, pages 1 - 4, XP000861812 *
MONTGOMERY S A: "EFFICACY OF NEFAZODONE IN THE TREATMENT OF DEPRESSION", JOURNAL OF PSYCHOPHARMACOLOGY,GB,OXFORD UNIVERSITY PRESS, vol. 10, no. SUPPL. 01, 1996, pages 5 - 10, XP000613043, ISSN: 0269-8811 *
NACCA ANGELO; GUISO GIOVANNA; FRACASSO CLAUDIA; CERVO LUIGI; CACCIA SILVIO: "Brain-to-blood partition and in vivo inhibition of 5-hydroxytryptamine reuptake and quipazine-mediated behaviour of nefazodone and its main active metabolites in rodents.", BRITISH JOURNAL OF PHARMACOLOGY, vol. 125, no. 7, December 1998 (1998-12-01), pages 1617 - 1623, XP000861819 *
SCHMIDER J ET AL: "Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation.", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, (1996 APR) 41 (4) 339-43., XP000861967 *

Also Published As

Publication number Publication date
JP2002541192A (en) 2002-12-03
AU4215400A (en) 2000-11-14
CA2369225A1 (en) 2000-10-19
EP1189616A2 (en) 2002-03-27
US6465469B1 (en) 2002-10-15
WO2000061129A2 (en) 2000-10-19

Similar Documents

Publication Publication Date Title
MXPA03007960A (en) Compounds and methods for the treatment of urogenital disorders.
WO1997015300A3 (en) Use of 4-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene for prophylaxis and treatment of sequelae of acute and chronic reduced circulation in the brain and neurodegenerative disorders
WO2001012170A3 (en) Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
HK1047693A1 (en) Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof
AU1213401A (en) Techniques using heat flow management, stimulation, and signal analysis to treatmedical disorders
AU2001273218A1 (en) Methods for stimulation of synthesis of synaptophysin in the central nervous system
GB2333453A (en) Colostrinin and uses thereof
IL201889A0 (en) Antibody recognizing nkt cells and uses thereof in the treatment of immune-related disorders
WO1998036764A3 (en) Method of treating psychological and metabolic disorders using igf or igf/igfbp-3
AU2002258428A1 (en) Methods for the treatment of metabolic disorders, including obesity and diabetes
AU5384799A (en) Silicon-containing titanium dioxyde, method for preparing the same and catalyticcompositions thereof
WO2004054558A3 (en) Reduction of breast density with 4-hydroxy tamoxifen
WO2001026638A3 (en) The use of baclofen in the treatment of alcoholism
WO2000061129A3 (en) S-hydroxynefazodone
AU2001251306A1 (en) Treatment of sleep disorders with hypocretin-1
WO2000061128A3 (en) R-hydroxynefazodone
AU2002304931A1 (en) Methods for treating disorders of the nervous and reproductive systems
EP1886681A3 (en) 5-(p-hydroxyphenyl)-3H-1,2-dithiol-3-thione valproate ester
WO2004009632A3 (en) Method for the production of an immunostimulating mucin (muc1)
MD916G2 (en) Ungent for stomatologic deseases treatment
WO2007019378A3 (en) Method of treating neurological disorders
Kuzhilna TRAGIC MODEL OF THE WORLD IN CULTURAL INTERPRETATION PERSONALITIES IN THE LYRICS OF SIXTY POETS IN UKRAINIAN LITERATURE OF THE XX CENTURY
WO2004045508A3 (en) Use of pde4 inhibitors as adjunct therapy for psychiatric disorders
TH122309A (en) L-threonine-producing bacteria of the Escherichia family and methods for producing L-threonine.
Sriram et al. The effects of stress on the respiratory system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2369225

Country of ref document: CA

Ref country code: CA

Ref document number: 2369225

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 610462

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000921897

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000921897

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000921897

Country of ref document: EP